[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mostafa Bahaa\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":204},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,63,83,102,123,143,161,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100574671","phase-2-efficacy-and-safety-of-empagliflozin-or-semaglutide-in-overweightobese-patients-with-type-1-diabetes-100574671",false,"NCT06762314","Efficacy and Safety of Empagliflozin or Semaglutide in Overweight\u002FObese Patients With Type 1 Diabetes","Comparative Clinical Study to Evaluate the Efficacy and Safety of Empagliflozin or Semaglutide in Overweight\u002FObese Patients With Type 1 Diabetes Inadequately Controlled by Insulin Therapy","Inclusion Criteria:\n\n* patients diagnosed with type 1 diabetes for more than 1 year.\n* Age 18-65 years.\n* BMI ≥ 27 kg\u002Fm².\n* HbA1c 7.5-10 % (58-86 mmol\u002Fmol)\n* Inadequately controlled despite treatment with multiple daily injections of insulin for at least 1 year.\n\nExclusion Criteria:\n\nHistory of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) syndrome; family history of multiple endocrine neoplasia, type 2A (MEN 2A), medullary thyroid cancer, or familial medullary thyroid cancer.\n\n* Insulin pump treatment.\n* Any prior use of GLP-1 RAs or dipeptidyl peptidase-4 inhibitors, any medication (except insulin) that could interfere with glycemic control or affect a subject's safety.\n* An estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m2.\n* Liver disease with raised alanine aminotransferase (AST), aspartate transaminase (ALT) or alkaline phosphatase (ALP)more than three times the upper normal range.\n* History of pancreatitis.\n* Gastroparesis.\n* Pregnancy or lactation.\n* History of alcohol or drug misuse, or any medical or psychological disorder that made the patient unsuitable for study participation.\n* Acute symptomatic urinary tract infection or genital infection; chronic or recurrent (≥3 annual episodes) cystitis.\n* Hypoglycaemia that required hospitalization or emergency treatment in the 3 months.\n* DKA that required hospitalization or emergency treatment in the past 12 months.\n* Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen leading to unstable body weight (based on Investigator's judgement) for the last 3 months.","ALL","18 Years","65 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Type 1 Diabetes (T1DM) is a disease characterised by immune mediated destruction of the insulin-producing pancreatic beta cells. Overtime, obvious insulin deficiency develops which requires insulin therapy. T1DM accounts for about 5% to 10% of diabetes cases in Europe and United States. Currently, worldwide incidence is estimated to be around 15 per 100,000 people per year. Despite the advancement that has occurred in the field diabetes therapy, patient with T1DM still suffer from managing their disease as well as continuing to face diabetes related complications. The American Diabetes Association (ADA) recommend a goal of glycated haemoglobin (HbA1c) of \\\u003C 7%. However, only 21% of adults in the United States has achieved this recommended goal. Once again, a multinational, multicentre study shows that only 24.3% of participants achieved the glycaemic target of HbA1c less than 7.0 %. Unfortunately, intensifying the insulin therapy in order to reach the targeted HbA1c can result in serious adverse effects of hypoglycaemia and weight gain which is in its turn is known risk factor for cardiovascular disease.",[27],"Diabetes","RECRUITING","2026-03-12",{"date":31,"type":32},"2026-03-13","ACTUAL",{"date":34,"type":32},"2025-01-20",{"date":36,"type":21},"2028-11-20",{"name":38,"class":39},"Mostafa Bahaa","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100533894","phase-3-metformin-safety-and-efficacy-in-osteoarthritis-100533894","NCT06231758","Metformin Safety and Efficacy in Osteoarthritis.","The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Primary osteoarthritis Patients recruited were between 30 to 60 years of age.\n* X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria.\n\nExclusion Criteria:\n\nPatients with age less than 30 years or more than 60 years Patients Presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug Patients Were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying OA of the hip of sufficient severity to interfere with the functional assessment of the knee Patients had previous or ongoing treatment with oral SYSDOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study Patients having a known hypersensitivity to the used medications Patients have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\\\u003C 10.0 g\u002F dl or haematocrit \\\u003C 30%).\n\nPatients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.","30 Years","60 Years",{"count":51,"type":21},70,[53],"PHASE3","Knee osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs and disability. It is estimated that over a third of people aged over 60 have radiographic knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their lifetime. At present there are no licensed treatments that alter disease progress and management is primarily concerned with symptom control to retain or improve joint function, although a trial of strontium ranelate showed promising results.",[56],"Osteo Arthritis Knee",{"date":31,"type":32},{"date":59,"type":32},"2024-01-30",{"date":61,"type":21},"2027-11-20",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":40},"100524815","phase-2-montelukast-in-parkinson-disease-100524815","NCT06113640","Montelukast in Parkinson Disease","Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease","Inclusion Criteria:\n\n\\- Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa\n\nExclusion Criteria:\n\n\\- Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and \u002F or drugs Known allergy to the studied medications","70 Years",{"count":72,"type":21},60,[24,53],"Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and\u002For rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.",[76],"Parkinson Disease",{"date":31,"type":32},{"date":79,"type":32},"2023-11-05",{"date":81,"type":21},"2026-12-20",{"name":38,"class":39},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":49,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100515025","phase-2-activation-of-autophagy-and-suppression-of-apoptosis-by-dapagliflozin-attenuates-inflammatory-bowel-disease-100515025","NCT05986136","Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both male and female will be\n* Mild and moderate UC patients diagnosed and confirmed by endoscope\n\nExclusion Criteria:\n\n* Breast feeding\n* Significant liver and kidney function abnormalities\n* Colorectal cancer patients\n* Patients with severe UC\n* Patients taking rectal or systemic steroids\n* Patients taking immunosuppressives or biological therapies\n* Addiction to alcohol and \u002F or drugs\n* Known allergy to the dapagliflozin","18 Months",{"count":91,"type":21},50,[24,53],"The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating\u002Fsevere diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex\u002Fmulti-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.",[95],"Inflammatory Bowel Diseases",{"date":31,"type":32},{"date":98,"type":32},"2023-08-20",{"date":100,"type":21},"2028-07-20",{"name":38,"class":39},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":17,"maxAge":49,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100508189","investigating-the-pathophysiological-nature-of-homosexuality-100508189","NCT05897177","Investigating the Pathophysiological Nature of Homosexuality","Investigating the Pathophysiological Nature of Homosexuality Patients in Egypt, England, China, and Mexico: Multicenter Study.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Male will be included\n\nExclusion Criteria:\n\n* Patients taking testosterone or its derivative.\n* Patients taking anabolic steroids.\n* Multi-sexual behaviours.\n* HIV patients.\n* not having and addictive disorder","MALE",{"count":111,"type":21},500,"OBSERVATIONAL","Debate continues on whether or not male homosexuality (MH) is a result of biological or cultural factors. The debate persists despite the fact that these two sides have different abilities to create a scientific environment to support their cause. Biological theorists produced evidence, however, that these are not always robust. On the other hand, social theorists, without direct evidence confirming their positions, criticize, with good argument, methods and results of the other side.",[115],"Psychiatric Disorder",{"date":117,"type":32},"2026-03-16",{"date":119,"type":32},"2023-07-20",{"date":121,"type":21},"2028-04-20",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":40},"100587151","phase-2-metformin-in-safety-and-efficacy-in-gouty-patients-100587151","NCT06924658","Metformin in Safety and Efficacy in Gouty Patients","the Impact of Metformin Use on Clinical Outcomes in Gouty Patients","Inclusion Criteria:\n\n* Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology\u002FEuropean League Against Rheumatism criteria of gout.\n\nExclusion Criteria:\n\n* Systemic disorders such as cardiovascular, neurological, coronary artery disease.\n* Hypertension, hyperlipidemia, diabetes mellitus, active infections.\n* Other inflammatory or autoimmune diseases.\n* Patients on biologics,\n* Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.",{"count":51,"type":21},[24],"The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients",[134],"Gout","2025-06-25",{"date":137,"type":32},"2025-06-27",{"date":139,"type":32},"2025-04-20",{"date":141,"type":21},"2026-11-20",{"name":38,"class":39},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":160,"locationsCount":40},"100592585","phase-2-comparative-clinical-and-biochemical-study-evaluating-the-effectiveness-of-metformin-versus-febuxostat-on-gouty-obese-non-diabetic-patients-100592585","NCT06995339","Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostate on Gouty Obese Non-Diabetic Patients","Inclusion Criteria:\n\n* Males or females aged \\\u003C 18 years.\n* All patients are diagnosed to have gout with serum uric acid \\\u003C 7 mg\u002Fdl.\n* All patients are diagnosed to have obesity with body mass index (BMI) ≥ 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n* The presence of any type of diabetes mellitus.\n* Patients with drug-induced hyperuriceamia (those taking anti-TB agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol).\n* Non-obese patients with BMI \\>30 kg\u002Fm2.\n* Pregnant or lactating women.",{"count":72,"type":21},[24],"Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\\>6.8 mg\u002Fdl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and around the joints forming tophi. Early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Lowering SUA levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. This results in dissolution of MSU crystals preventing further attacks",[134],"2025-06-21",{"date":156,"type":32},"2025-06-24",{"date":158,"type":32},"2025-05-30",{"date":81,"type":21},{"name":38,"class":39},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":168,"maxAge":49,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100541439","phase-1-doxycycline-in-type-ii-diabetes-100541439","NCT06329882","Doxycycline in Type II Diabetes","Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5\n\nExclusion Criteria:\n\n* Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation","40 Years",{"count":72,"type":21},[171,24],"PHASE1","Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden",[174],"Diabetes Mellitus, Type 2","2025-04-03",{"date":177,"type":32},"2025-04-04",{"date":179,"type":32},"2024-03-30",{"date":181,"type":21},"2026-04-20",{"name":38,"class":39},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":40},"100488205","phase-2-clinical-study-evaluating-safety-of-pentoxifylline-and-celecoxib-in-patients-with-grand-mal-epilepsy-treated-by-phenytoin-monotherapy-100488205","NCT05637086","Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","Clinical Study Evaluating and Comparing the Safety and the Possible Efficacy of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","Inclusion Criteria:\n\n\\- Patients aged ≥ 18 years old. Patients with grand mal epilepsy on phenytoin monotherapy. Women with a negative pregnancy test and women on effective contraception\n\nExclusion Criteria:\n\n\\- Patients with significant liver and kidney function abnormalities. Alcohol and\u002For drug abusers. Patients with known allergies to the study medications Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).\n\nPregnant women and women with a planned pregnancy. Subjects on medication are known to have possible positive effects on epilepsy. Patients who are currently using other antiepileptic drugs. Patients with CVD and a history of coronary artery bypass graft (CABG) surgery. Patients on aspirin or fluconazole therapy Patients with a recent retinal or cerebral hemorrhage","75 Years",{"count":192,"type":21},90,[24],"Epilepsy is a chronic neurological disorder affecting millions of people all over the world. Epileptic seizures are caused by abnormal synchronized electrical neuronal discharges that could be either focal or widespread. Pathogenesis of epilepsy involves multiple processes including genetics, oxidative stress, ion channels, neuroinflammation, and cellular damage through autophagy and apoptosis.\n\nNeuroinflammation is considered one of the most important factors contributing critically to epileptogenesis.",[196],"Epilepsy","2024-07-16",{"date":199,"type":32},"2024-07-18",{"date":201,"type":32},"2022-12-20",{"date":61,"type":21},{"name":38,"class":39},""]